Holen Sie sich die Stockscreener-App
36.99
0.78%
-0.29
Schlusskurs vom Vortag:
$37.28
Offen:
$37.72
24-Stunden-Volumen:
388.88K
Relative Volume:
1.16
Marktkapitalisierung:
$1.19B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.95M
KGV:
-24.90
EPS:
-1.4857
Netto-Cashflow:
$-50.43M
1W Leistung:
-0.91%
1M Leistung:
-25.24%
6M Leistung:
+43.99%
1J Leistung:
+139.26%
1-Tages-Spanne:
$36.75
$38.81
1-Wochen-Bereich:
$36.57
$39.23
52-Wochen-Spanne:
$14.32
$50.16
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Firmenname
Lb Pharmaceuticals Inc
Sektor
Branche
Telefon
917-450-6581
Adresse
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
36.99 | 1.20B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-09 | Eingeleitet | Roth Capital | Buy |
| 2025-10-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-06 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-06 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat
LB Pharmaceuticals at TD Cowen summit: lb-102 aims for safer psychiatry - Investing.com Nigeria
LB Pharmaceuticals rated buy with $85 base value, $150 potential if Phase 3 succeeds by 2027 - Pluang
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity - Seeking Alpha
LB Pharmaceuticals Inc (LBRX) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Form 8K LB Pharmaceuticals Inc For: 15 September By Investing.com - Investing.com Australia
LB Pharmaceuticals names Susan Kozauer as chief medical officer By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Names Dr. Susan Kozauer as Chief Medical Officer with Detailed Compensation Package - Kalkine Media
LB Pharmaceuticals names Susan Kozauer as chief medical officer - Investing.com
LB Pharmaceuticals Names Susan Kozauer Chief Medical Officer Ahead of Phase 3 Readout - citybiz
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer - GlobeNewswire
LB Pharmaceuticals (LBRX) CFO reports zero share ownership - Stock Titan
Bank of America Corp DE Has $410,000 Stock Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bank of New York Mellon Corp Makes New $1.78 Million Investment in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Names Joseph M. Miller as CFO with $530K Salary and 200,000-Share Stock Option - Kalkine Media
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment - Yahoo Finance
LB Pharmaceuticals to Participate in Upcoming September Investor Events - GlobeNewswire
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - Kalkine Media
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.3%Here's What Happened - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Appoints Joseph M. Miller as CFO with $530K Salary and Equity Incentives - kalkinemedia.com
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
LB Pharmaceuticals Appoints Joseph Miller as New CFO - TipRanks
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer - The Manila Times
LBRX Q2 2026 Earnings: 108.7% EPS Miss Reflects Escalating Clinical Spend; Stock Moves Up 4.97%Special Dividend Alert - dars.gov.et
LB Pharmaceuticals (LBRX) Edges Lower to $47.14 as Support HoldsHull Moving Average - careplusvn.com
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Forecast for LBRX Earnings - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High After Analyst Upgrade - MarketBeat
H.C. Wainwright raises LB Pharmaceuticals price target to $60 By Investing.com - Investing.com India
H.C. Wainwright raises LB Pharmaceuticals price target to $60 - Investing.com
Great Lakes Advisors LLC Purchases Shares of 30,410 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighTime to Buy? - MarketBeat
LB (LBRX) Technical Check: Climbs 1.88% to $47.10 on the Day; Level Position: the $44.74 to $49.46 Range Remains in FocusPositive Gamma - vinanet.vn
LBRX Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.92%EPS Growth Report - dars.gov.et
LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen - marketbeat.com
LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A - Stock Titan
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com South Africa
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook - Investing.com
Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $53 - Moomoo
LB Pharmaceuticals (LBRX) Slips 2.45% as Key Support Levels Come into FocusMarket Cap Weight - dars.gov.et
LB PHARMACEUTICALS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $55 FROM $40 - webull.com
LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) Stock Price, News & Analysis - Kalkine
BMO Capital Markets Increases LB Pharmaceuticals (NASDAQ:LBRX) Price Target to $54.00 - MarketBeat
LBRX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Form 8K LB Pharmaceuticals Inc For: 11 August - Investing.com India
LB Pharmaceuticals Inc Stock 12‑Month Price Target Raised to $47.67, Implies 4% Upside - TradingView
LB Pharmaceuticals Submits Q2 2026 SEC Form 10-Q Reporting 32.26M Shares Outstanding - Kalkine Media
LB Pharmaceuticals2026 Funding Rounds & List of Investors - tracxn.com
LB Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Finanzdaten der Lb Pharmaceuticals Inc-Aktie (LBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):